2 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMOCompleted
The aim of the present study is to examine the effect of integrated telemonitoring and telecare, compared to usual care, on quality of life and hospitalization in patients with heart failure in primary care.PrimaryTo examine the effect of integrated…